Acute graft-versus-host disease (aGVHD) can affect the central nervous system (CNS) through microglial activation and T cell infiltration, but the role of gut microbiota in CNS-aGVHD remains unclear. Here, we investigated the role of microbiota in microglial activation during aGVHD using antibiotic-treated specific pathogen–free (SPF), germ-free (GF), and wildling mice. Antibiotic-mediated microbiota depletion led to infiltration of IFN-γ–producing T cells in the brain, activation of microglia via the TLR4/p38 MAPK pathway, and neurocognitive deficits in SPF aGVHD mice. Microglial depletion reversed the neurocognitive deficits. GF and wildling mice treated with antibiotics exhibited similar microglial activation after allogeneic hematopoietic cell transplantation (allo-HCT). Mechanistically, the bacteria-derived metabolite N,N,N-trimethyl-5-aminovaleric acid (TMAVA) was decreased in microglia following antibiotic treatment. TMAVA administration suppressed TLR4/p38 MAPK pathway activity in microglia and alleviated gut microbiota depletion–mediated neurocognitive deficits. Additionally, TMAVA abundance decreased in patient blood after allo-HCT and after GVHD onset. In summary, we identify TMAVA loss as a central causative factor for CNS-aGVHD, opening new perspectives for a metabolite-based therapy.
Gut microbiota–derived TMAVA is a modulator of acute CNS-GVHD
Disclosures: P. Apostolova reported other from Pfizer and grants from Novartis outside the submitted work. D. Michonneau reported grants from Novartis, grants from Sanofi, grants from CSL Behring, personal fees from Incyte, personal fees from Novartis, personal fees from Jazz Pharma, and personal fees from Sanofi outside the submitted work. R. Zeiser reported personal fees from Novartis, personal fees from Therakos, and personal fees from Medac outside the submitted work. No other disclosures were reported.
- Award Id(s): 2021/A2-Fol,2021/B3-Fol
- Award Id(s): 450392965,259373024,441891347,256073931,431984000,491676693,471011418,493802833,872/4-1,ZE 872/7-1,ZE 872/8-1,RO 6247/1-1,446316360,256073931,491676693
- Award Id(s): 101094168
- Award Id(s): 70114655,70116490
- Award Id(s): DJCLS 09R/2022
- Award Id(s): 7030-23
- Award Id(s): 390939984,560868983
- Award Id(s): 10.001.317
- Award Id(s): 24C246
- Award Id(s): 2015_A147
- Award Id(s): 01ZZ2322A,01ZZ2015
- Award Id(s): 101119855
Sangya Chatterjee, Tamina Rückert, Ina Martin, Elisa Michaeli, Joerg Buescher, Petya Apostolova, Daniel Erny, Maria-Eleni Lalioti, Francesca Biavasco, Alina Hartmann, Solveig Runge, Lukas M. Braun, Nana Talvard-Balland, Rachael C. Adams, Annette Schmitt-Graeff, James Cook, Valentin Wenger, Dimitrios Athanassopoulos, Dilara Hasavci, Alexander Paolo Vallejo-Janeta, Thomas Blank, Philipp Schaible, Janaki Manoja Vinnakota, Alexander Zähringer, Stephanie C. Ganal-Vonarburg, Wolfgang Melchinger, Dietmar Pfeifer, Natalie Köhler, Stephan P. Rosshart, David Michonneau, Gérard Socié, Geoffroy Andrieux, Nina Cabezas-Wallscheid, Melanie Boerries, Marco Prinz, Robert Zeiser; Gut microbiota–derived TMAVA is a modulator of acute CNS-GVHD. J Exp Med 1 September 2025; 222 (9): e20242180. doi: https://doi.org/10.1084/jem.20242180
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement